Semaglutide before IVF to improve embryo quality for overweight and obese women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Overweight and obese women up to 38 years old with preserved ovarian reserve (AMH ≥1 ng/mL or AFC ≥6) and BMI 27–40 kg/m² are randomized 1:1 to 12 weeks of semaglutide pre-treatment or no pre-treatment before standard ovarian stimulation. Embryos are cultured to blastocyst stage and cryopreserved using a freeze-all strategy, with transfers in the semaglutide group after an 8-week washout. The primary outcome is the number of good-quality blastocysts on day 5, and secondary outcomes include fertilization rate, embryo morphokinetics, numbers of MII oocytes and COCs, total blastocyst formation rate, and metabolic changes. The study is powered to detect a difference of 1.5 good-quality blastocysts between groups with 80% power and a two-sided alpha of 0.05.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≤ 38 years
* AMH \>= 1 ng/mL or AFC \>= 6
* Body mass index (BMI) between 27 kg/m2 and 40 kg/m2
* Scheduled for IVF with freeze-all strategy

Exclusion Criteria:

* Severe male factor (sperm concentration \<5M/mL)
* Type 2 diabetes mellitus
* Prior use of GLP-1 Ras within the past year
* Uncontrolled thyroid disorders
* Contraindications to IVF or semaglutide treatment
* Patients with chronic inflammatory diseases
* Family history of hereditary or chromosomal diseases
* Use of glucocorticoids or immunosuppressants
* PGT-A
* Use of medications affecting metabolism or inflammation

Where it's running

• Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus
  Barcelona, Spain Recruiting
• Dexeus Mujer Sabadell
  Sabadell, Barcelona, Spain Not yet recruiting
• Dexeus Mujer Sant Cugat
  Sant Cugat del Vallès, Barcelona, Spain Not yet recruiting
• Dexeus Mujer Reus
  Reus, Tarragona, Spain Not yet recruiting
• Dexeus Mujer Tarragona
  Tarragona, Spain Not yet recruiting

Study contacts

• Principal investigator: Nikolaos P Polyzos, MD, PhD — Dexeus Fertility
• Study coordinator: Nikolaos P Polyzos, MD, PhD
• Email: nikpol@dexeus.com
• Phone: 0034932274700

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using liraglutide to improve fertility in obese women with PCOS

  This study is testing if giving liraglutide, along with metformin, can help obese women with PCOS improve their chances of having a baby through IVF by losing weight and getting healthier.

  Recruiting Phase 4 Peking University Third Hospital · Beijing, Beijing Municipality and 2 other locations · NCT06742710

• Pulsatile FSH treatment for women with obesity to improve fertility

  This study is testing if a new way of giving hormone treatment can help women with obesity who are having trouble getting pregnant.

  Recruiting Phase 1 University of Colorado, Denver · Aurora, Colorado · NCT06414096

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.